Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.72 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.72 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.72 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.72 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.72 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.72 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.72 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.72 |
| ▸ | RXRA | P19793 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8142250 | 1.00 | PPARG (0.72) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8142252 | 1.00 | PPARG (0.72) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8150057 | 0.91 | PPARG (0.60) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8150061 | 0.91 | PPARG (0.60) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8150063 | 0.91 | PPARG (0.60) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL7630967 | 0.90 | RXRA (0.60) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8681652 | 0.89 | PPARG (0.64) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL8681649 | 0.89 | PPARG (0.64) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL21845816 | 0.87 | PPARG (0.59) | PPARGCYP1A2MAPTMAPK1PTGS2 | |
| SCHEMBL29546935 | 0.87 | PPARG (0.59) | PPARGCYP1A2MAPTMAPK1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-5776962-A | Lactone compounds for treating patient with precancerous lesions | CELL PATHWAYS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5696159-A | Lactone compounds for treating patients with precancerous lesions | CELL PATHWAYS, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | PPARG 18/4885CYP1A2 2296/4885MAPT 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.